Ilyang Pharmaceutical Co Ltd (007575) — Cash Flow Reinvestment Rate
Ilyang Pharmaceutical Co Ltd (007575) has a Cash Flow Reinvestment Rate of 3.94x as of June 2025, reinvesting ₩8.90 Billion (capex ₩3.32 Billion plus investments ₩-5.59 Billion) from operating cash flow of ₩2.26 Billion. Check 007575 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Ilyang Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2014–2024)
Historical reinvestment intensity for Ilyang Pharmaceutical Co Ltd across 11 annual periods. Explore long-term investment intensity of Ilyang Pharmaceutical Co Ltd to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Ilyang Pharmaceutical Co Ltd (2014–2024)
Year-by-year capital reinvestment analysis for Ilyang Pharmaceutical Co Ltd. For live market cap and broader valuation context, see Ilyang Pharmaceutical Co Ltd stock valuation.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 13.86x | ₩77.80 Billion | ₩5.61 Billion | ₩40.62 Billion | ▲ +1004.0% |
| 2023 | 1.26x | ₩18.35 Billion | ₩14.62 Billion | ₩6.83 Billion | ▲ +16.7% |
| 2022 | 1.08x | ₩32.20 Billion | ₩29.94 Billion | ₩4.08 Billion | ▲ +434.9% |
| 2021 | 0.20x | ₩13.48 Billion | ₩67.02 Billion | ₩12.91 Billion | ▲ +12.3% |
| 2020 | 0.18x | ₩10.29 Billion | ₩57.48 Billion | ₩10.17 Billion | ▼ -25.2% |
| 2019 | 0.24x | ₩8.67 Billion | ₩36.19 Billion | ₩2.17 Billion | ▲ +104.4% |
| 2018 | 0.12x | ₩2.59 Billion | ₩22.12 Billion | ₩1.55 Billion | ▼ -53.7% |
| 2017 | 0.25x | ₩7.60 Billion | ₩30.03 Billion | ₩3.78 Billion | ▼ -67.4% |
| 2016 | 0.78x | ₩20.98 Billion | ₩26.98 Billion | ₩10.31 Billion | ▲ +87.2% |
| 2015 | 0.42x | ₩16.72 Billion | ₩40.27 Billion | ₩16.07 Billion | ▼ -44.4% |
| 2014 | 0.75x | ₩13.92 Billion | ₩18.63 Billion | ₩13.89 Billion | — |